Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
D’Arcy Masius Benton & Bowles has won the estimated $60 million-plus creative account for the over-the-counter version of Pravachol, which as yet has no launch date, sources said.
The cholesterol-reducing drug from Bristol-Myers Squibb will continue to be available in prescription form even after the OTC version is introduced, sources said. The OTC Pravachol is awaiting the FDA’s approval.
It is believed Bozell Worldwide in New York will continue to handle the Rx Pravachol and was one of the contenders in the four-month review.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in